A detailed history of Black Rock Inc. transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 830,371 shares of KZR stock, worth $448,400. This represents 0.0% of its overall portfolio holdings.

Number of Shares
830,371
Previous 4,616,988 82.01%
Holding current value
$448,400
Previous $4.16 Million 88.01%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.6 - $0.92 $2.27 Million - $3.48 Million
-3,786,617 Reduced 82.01%
830,371 $498,000
Q1 2024

May 10, 2024

SELL
$0.8 - $1.05 $160,222 - $210,291
-200,278 Reduced 4.16%
4,616,988 $4.16 Million
Q4 2023

Feb 13, 2024

SELL
$0.72 - $1.15 $97,217 - $155,277
-135,024 Reduced 2.73%
4,817,266 $4.58 Million
Q3 2023

Nov 13, 2023

SELL
$1.08 - $2.54 $147,805 - $347,616
-136,857 Reduced 2.69%
4,952,290 $5.89 Million
Q2 2023

Aug 11, 2023

BUY
$2.31 - $3.06 $1.46 Million - $1.93 Million
631,157 Added 14.16%
5,089,147 $12.5 Million
Q1 2023

May 12, 2023

BUY
$3.13 - $7.31 $710,751 - $1.66 Million
227,077 Added 5.37%
4,457,990 $14 Million
Q4 2022

Feb 13, 2023

BUY
$6.39 - $8.8 $805,037 - $1.11 Million
125,984 Added 3.07%
4,230,913 $29.8 Million
Q3 2022

Nov 14, 2022

BUY
$7.99 - $10.75 $4.2 Million - $5.65 Million
525,139 Added 14.67%
4,104,929 $35.3 Million
Q2 2022

Aug 12, 2022

BUY
$4.58 - $17.13 $3.13 Million - $11.7 Million
682,716 Added 23.57%
3,579,790 $29.6 Million
Q1 2022

May 12, 2022

BUY
$12.3 - $18.33 $2.58 Million - $3.85 Million
210,050 Added 7.82%
2,897,074 $48.2 Million
Q4 2021

Feb 10, 2022

BUY
$7.44 - $16.72 $410,747 - $923,077
55,208 Added 2.1%
2,687,024 $44.9 Million
Q3 2021

Nov 09, 2021

BUY
$4.85 - $9.73 $155,263 - $311,486
32,013 Added 1.23%
2,631,816 $22.7 Million
Q2 2021

Aug 11, 2021

BUY
$4.93 - $6.46 $12.8 Million - $16.8 Million
2,599,803 New
2,599,803 $14.1 Million

Others Institutions Holding KZR

About Kezar Life Sciences, Inc.


  • Ticker KZR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,369,504
  • Market Cap $36.9M
  • Description
  • Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...
More about KZR
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.